1. Clinical Overview of HGH Fragment 176-191
Molecule: Synthetic peptide derivative comprising amino acids 176 to 191 of the native human growth hormone (hGH) molecule. This C-terminal fragment retains the fat-reducing properties of hGH without undesired effects on insulin sensitivity or IGF-1 elevation.
Classification: GH Fragment (Modified C-terminal) · Lipolytic peptide (non-anabolic) · Selective fat-loss agent
Clinical Significance
- Promotes lipolysis in adipose tissue
- Inhibits lipogenesis
- No significant impact on blood glucose, IGF-1, or insulin resistance
- Lacks GH-related mitogenic or anabolic effects
2. Mechanisms of Action
2.1 Targeted Lipolysis
- Stimulates hormone-sensitive lipase activity in adipocytes
- Promotes release of free fatty acids and glycerol
2.2 Inhibition of Lipogenesis
- Reduces de novo fatty acid synthesis in visceral fat depots
- Modulates insulin-induced lipogenic enzymes
2.3 Selectivity Without Anabolism
- No effect on linear growth or muscle hypertrophy
- Does not elevate IGF-1 levels significantly
2.4 Energy Mobilization Enhancement
- Increases availability of fatty acids for β-oxidation
- May contribute to improved endurance and energy balance
3. Evidence Summary — Clinical Domains
3.1 Fat Loss & Body Composition
Notable reduction in abdominal and visceral fat mass. Body composition improvements in animal and human pilot studies.
3.2 Metabolic Regulation
Preserved insulin sensitivity vs. hGH. May enhance fatty acid oxidation without glucose intolerance.
3.3 Adjunctive Weight Loss Therapy
Synergistic with caloric restriction or GLP-1 agonist protocols. May reduce plateaus in fat loss phases.
4. Clinical Protocols
4.1 Administration Route
Subcutaneous injection (abdomen preferred). Daily or twice-daily administration recommended.
4.2 Reconstitution
2 mg lyophilized vial · Reconstitute with 2 mL bacteriostatic saline · Final concentration: 1 mg/mL
4.3 Dosing Guidelines
Standard Fat Loss Protocol: 250 mcg BID (morning fasted and pre-bed) · Duration: 4–8 weeks
Advanced Recomposition Protocol: 300–500 mcg BID or 1× daily (AM fasted) · Combine with caloric restriction and exercise · Duration: 8–12 weeks
Adjunct Protocol with GLP-1 Agonists: 250 mcg/day · May enhance fat oxidation during metabolic therapy
5. Clinical Integration Strategies
5.1 HGH Fragment 176-191 + GLP-1 (Semaglutide, Tirzepatide, Mazdutide)
Amplifies visceral fat loss. May prevent lean mass loss from aggressive GLP-1 therapy.
5.2 HGH Fragment + 5-Amino-1MQ
NNMT inhibition + lipolytic synergy. Effective for metabolically stubborn fat regions.
5.3 HGH Fragment + MOTS-c or SLU-PP-332
Mitochondrial optimization for improved fat oxidation. Combines well with endurance or fasting protocols.
5.4 HGH Fragment + REVIVE™ AM Stack
Supports liver lipid metabolism. May enhance energy and mobilization in AM fasted state.
6. Decision Tree for Clinical Use
| Scenario | HGH Fragment Use |
|---|
| Fat loss w/o IGF-1 increase desired | Ideal candidate |
| Visceral adiposity | Strong indication |
| Muscle growth desired | Not suitable alone |
| Insulin resistance present | Appropriate (no glucose impact) |
| Budget-sensitive patient | Consider alternative agents |
7. Safety, Side Effects & Monitoring
7.1 Side Effects
- Mild local irritation or redness at injection site
- Rare nausea or headache
- Transient fatigue in fasting states
7.2 Contraindications
- Pregnancy and breastfeeding
- Active malignancy (precautionary)
- Known hypersensitivity to GH analogs
7.3 Monitoring
- Waist circumference, visceral fat scans (DEXA/MRI optional)
- Weight and body fat percentage
- Optional: fasting glucose, HOMA-IR for longitudinal protocols
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
HGH Fragment 176-191, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — HGH Fragment 176-191 Clinical Reference Guide
1. Heffernan, M., et al. (2001). Effects of hGH Fragment 176-191 on Body Composition and Lipolysis in Rodents. Endocrinology, 142(5), 1878–1883.
2. Ng, F. M., et al. (2000). Lipolytic Action of a Fragment of Human Growth Hormone (176-191) in Obese Zucker Rats. Journal of Endocrinology, 167(1), 129–137.
3. Sainsbury, A., et al. (2006). Selective fat loss with growth hormone fragment 176-191 in obese mice: Absence of diabetogenic or mitogenic effects. Diabetologia, 49(3), 442–448.
4. Cui, T., et al. (2010). GH Fragment 176-191 improves adiposity and lipid profile in high-fat diet-induced obese rats. Peptides, 31(10), 1801–1806.
5. Le Roith, D., et al. (2001). Role of IGF-1 and GH Fragment Derivatives in Adipose and Metabolic Regulation. Growth Hormone & IGF Research, 11(Suppl A), S123–S126.
6. Wraight, C. J., et al. (1996). The C-terminal hGH Fragment 176-191 reduces body fat in obese mice independently of IGF-1. American Journal of Physiology-Endocrinology and Metabolism, 270(6), E1040–E1047.